Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00034905 · ClinicalTrials.gov registry record · Phase 4
A Comparison of Seroquel vs. Risperidone in Schizophrenia
A Phase 4 study of Schizophrenia, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Study locations
NCT00034905 is a Phase 4 study of Schizophrenia that has completed, run by AstraZeneca. The trial reports 20 study locations across 8 states.
The verdict
NCT00034905, a Phase 4 study of Schizophrenia, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20
- Study locations
Study Summary
The purpose of this study is to show equal efficacy of both quetiapine and risperidone in subjects treated with study medication for up to 8 weeks.
Conditions Studied
Interventions
- DRUG quetiapine fumarate vs risperidone
Study Locations (20)
California
- - Anaheim
- - Cerritos
- - Chula Vista
- - Glendale
- - Hawthorne
- - Long Beach
- - San Diego
- - Santa Ana
- - Torrance
Florida
- - Miami
- - Miami Beach
- - North Miami
- - Winter Park
Connecticut
- - Farmington
- - New Haven
Alabama
- - Birmingham
Arizona
- - Phoenix
District of Columbia
- - Washington D.C.
Georgia
- - Atlanta
Illinois
- - Hoffman Estates
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-07 |
| Est. Completion | 2002-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00034905
The ClinicalTrials.gov registry entry for NCT00034905 describes a study currently listed as completed, categorized as Phase 4. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which quetiapine fumarate vs risperidone is the first listed.
NCT00034905 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00034905 about?
NCT00034905 is a clinical study titled "A Comparison of Seroquel vs. Risperidone in Schizophrenia". The purpose of this study is to show equal efficacy of both quetiapine and risperidone in subjects treated with study medication for up to 8 weeks.
What is the current status of trial NCT00034905?
This trial is currently completed. It is a Phase 4 study. The study started on 2001-07. Estimated completion is 2002-09.
What conditions does trial NCT00034905 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00034905?
The interventions under investigation include: quetiapine fumarate vs risperidone (DRUG).
Who is sponsoring clinical trial NCT00034905?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00034905 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
CLOZAPINE Response in Biotype-1
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
RECRUITING · Phase 4
-
Anti-Inflammatory Challenge in Schizophrenia
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.